Residual Inflammatory Risk-Guided colcHicine in Elderly Trial

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

800

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions

Percutaneous Coronary InterventionMultivessel Coronary Artery DiseaseElderly PatientsC-Reactive Protein

Interventions

DRUG

colchicine

Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.

Trial Locations (1)

Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS & PUMC, Beijing

All Listed Sponsors

lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial | Biotech Hunter | Biotech Hunter